Physician profile
Patrick J Madden
NPI 1134187073
$2,552.63
in general payments reported to CMS, 2019-2025
27 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.08 · 2020: $244 · 2021: $382 · 2022: $269 · 2023: $556 · 2024: $916 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $307.92 | 2019-2024 | Mavenclad |
| Neurocrine Biosciences, INC. | $216.85 | 2020-2025 | Ingrezza, Ongentys |
| Amgen INC. | $212.84 | 2020-2022 | |
| Argenx US, INC. | $195.51 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $194.50 | 2023-2024 | Hizentra |
| Abbvie INC. | $168.14 | 2021-2025 | |
| Pfizer INC. | $148.57 | 2023-2025 | |
| Ucb, INC. | $143.88 | 2019-2025 | Zilbrysq, Cimzia, Rystiggo |
| Takeda Pharmaceuticals U.S.A., INC. | $128.20 | 2023-2024 | Hyqvia |
| Lilly USA, LLC | $92.44 | 2021-2025 | Amyvid, Kisunla |
| Biogen, INC. | $91.71 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $73.93 | 2024-2025 | Xtampza |
| Novartis Pharmaceuticals Corporation | $68.35 | 2023-2024 | |
| Curonix LLC | $66.27 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Acadia Pharmaceuticals INC | $59.88 | 2023-2024 | Nuplazid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $56.21 | 2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $54.56 | 2019-2024 | Austedo Xr |
| Allergan, INC. | $47.43 | 2020 | |
| Eisai INC. | $47.36 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.37 | 2022 | |
| Vanda Pharmaceuticals INC. | $34.79 | 2020-2021 | |
| Neurelis, INC. | $24.61 | 2024 | Valtoco |
| Janssen Pharmaceuticals, INC | $19.25 | 2022 | |
| Sobi, INC | $17.89 | 2024 | |
| Relievant Medsystems, INC. | $17.63 | 2023 | Intracept |
| Arbor Pharmaceuticals, INC. | $16.43 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Madden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.